Docket No. 29888-5

CERTIFICATE OF MAILING

<u>PATENT</u>

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA

223/3-1450 on Ogc. 16, 200

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Mallen Huang

Paper No.:

Serial No.:

10/551,804

Group Art Unit:

Filing Date:

September 30, 2005

Examiner:

For:

Nucleotide Vaccine Composition

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56 and 1.97-1.98, Applicants cite the references listed on the attached Form PTO-1449. Copies of the non-U.S. patent references are enclosed.

Since the present statement is submitted prior to a first Official Action, no statement or fee under 37 C.F.R. §1.97 is required (37 C.F.R. §1.97(b)(1)).

Please charge any fee required in connection with this Statement to Deposit Account 04-1133.

Respectfully submitted,

Holly D. Kozlowski/Reg. No. 30,468

Dinsmore & Shohl LLP 1900 Chemed Center

255 East Fifth Street Cincinnati, Ohio 45202

(513) 977-8568

1215772v1

PTO FORM 4/92 Page 1 of 1														
LIST OF PATENTS AND PUBLICATIONS APPL FOR APPLICANT'S INFORMATION FILIN									PPLICANT: Mallen Huang LING DATE: September 30, 2005 DR: Nucleotide Vaccine Composition			SERIAL NO.: 10/551,804 GROUP:		
		τ	INITI	ED ST	rate:	S LETT	ERS	PATE	NT					
Exr. Init.		DOCUMENT NUMBER							DATE	NAME		CLASS	SUB CLASS	
						<u> </u>				<u></u>				
_					+	<u> </u>					· · ·			
					 	-	<u> </u>			_				
	_			-				-						
					†									
	.,													
		FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER							DATE	COUNTRY		CLASS	SUB CLASS	
/S.F./	aa	01	1	1	0 .	6	7		Feb. 15, 2001	PCT				
/S.F./	ab	00	5	4	8	3	9		Sept. 21, 2000	PCT				
S.F./	ac	96	0	0	2	5	5		Feb. 1, 1996	PCT				
					+				,					
				-	+		<u> </u>							
					+		 	- -						
						1								
ОТНЕ	R AR	T (INC	LUD	ING A	AUTH	OR, TI	rle i	DATE, P	PERTINENT PAGE	ES, ETC.)		<u> </u>	1	
/S.F./	ac	Ruobing Wang et al, "Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine", Science, Vol. 282, October, 1988, pp. 476-480.												
/S.F./	ad	John J. Donnelly et al, "DNA Vaccines", Annu. Rev. Immunol., 1997, 15:617-48.												
/S.F.	ae .	Sanjay Gurunathan et al, "DNA Vaccines: Immunology, Application, and Optimization", Annu. Rev. Immunol., 2000, 18:927-974.												
/S.F./	af	John M. Timmerman et al, "Dendritic Cell Vaccines for Cancer Immunotherapy", Annu. Rev. Med., 1999, 50:507-529.												
/S.F./	ag	Ching-Hsiang Hsu et al, "Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization", Nature Medicine, Volume 2, Number 5, May 1996, pp. 540-544.												
S.F./	ah	Ari Waisman et al, "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity", <i>Nature Medicine</i> , Volume 2, Number 8, August 1996, pp. 899-905.												
/S.F.	ai / `	Keiichi Kontani et al, "Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model", <i>Cancer Gene Therapy</i> ", 2002, 9, 330, 337.												
			<u> </u>											
1														

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1215802v1